Archives
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Thiazovivin and the Future of Cellular Plasticity: Mechan...
2025-10-04
This thought-leadership article explores the transformative role of Thiazovivin, a potent ROCK inhibitor, in enhancing cell reprogramming, stem cell survival, and translational applications targeting cellular plasticity. Integrating mechanistic analysis, experimental validation, and strategic recommendations, it contextualizes Thiazovivin within the rapidly evolving landscape of regenerative medicine and differentiation therapy, offering actionable guidance and a visionary perspective for researchers.
-
Ferrostatin-1: Selective Ferroptosis Inhibitor for Robust...
2025-10-03
Ferrostatin-1 (Fer-1) stands as the gold standard for dissecting iron-dependent oxidative cell death, offering unmatched selectivity and reproducibility in ferroptosis assays. Its utility spans cancer biology, neurodegenerative, and ischemic injury models, empowering researchers to advance mechanistic discoveries and therapeutic innovation.
-
Ferrostatin-1: Selective Ferroptosis Inhibitor for Transl...
2025-10-02
Ferrostatin-1 (Fer-1) uniquely enables researchers to dissect iron-dependent oxidative cell death in cancer biology, neurodegeneration, and ischemic injury models. Its high potency and selectivity for lipid peroxidation pathways deliver robust, reproducible results—empowering next-generation ferroptosis assays. Discover how Fer-1 transforms experimental workflows and overcomes common pitfalls in ferroptosis inhibition.
-
Unlocking Cellular Plasticity: Thiazovivin and the Future...
2025-10-01
This thought-leadership article provides translational researchers with a rigorous, forward-looking roadmap to harnessing Thiazovivin—a potent ROCK inhibitor—for next-generation cell reprogramming and survival strategies. Blending mechanistic insight, experimental validation, and cross-disciplinary innovation, we reframe how Thiazovivin can be leveraged to advance regenerative medicine, disease modeling, and differentiation therapy, with a special focus on the translational edge it provides over conventional approaches.
-
Thiazovivin: Unraveling ROCK Inhibition for Superior Stem...
2025-09-30
Explore how Thiazovivin, a potent ROCK inhibitor, uniquely enhances fibroblast reprogramming and human embryonic stem cell survival. This in-depth analysis delves into its mechanistic impact on the ROCK signaling pathway, with fresh insights distinct from prior reviews.
-
Y-27632 Dihydrochloride: Unlocking Rho/ROCK Pathways for ...
2025-09-29
Explore how Y-27632 dihydrochloride, a potent and selective ROCK inhibitor, is revolutionizing the study of Rho/ROCK signaling in advanced neuro-epithelial co-culture systems. This in-depth analysis reveals unique applications in microfluidic gut models and highlights opportunities beyond conventional stem cell or cancer research.
-
Ferrostatin-1 (Fer-1): Mechanistic Insights and Emerging ...
2025-09-28
Explore the advanced mechanistic role of Ferrostatin-1 (Fer-1) as a selective ferroptosis inhibitor in cancer, neurodegeneration, and ischemic injury. This in-depth review presents unique scientific analysis and translational perspectives not found in standard guides.
-
Y-27632 Dihydrochloride: Advanced ROCK Inhibition in Dyna...
2025-09-27
Explore the multifaceted role of Y-27632 dihydrochloride, a selective ROCK inhibitor, in modulating intestinal stem cell (ISC) niche dynamics and tumor suppression. This in-depth analysis offers unique insights into Rho/ROCK pathway manipulation for regenerative medicine and cancer research.
-
Y-27632 Dihydrochloride: Unraveling ROCK Inhibition for I...
2025-09-26
Explore the advanced roles of Y-27632 dihydrochloride as a selective ROCK inhibitor in engineering intestinal stem cell (ISC) niches. This in-depth analysis reveals novel strategies for regenerative medicine and cancer research, setting it apart from conventional perspectives.
-
WY-14643 (Pirinixic Acid): Unraveling PPARα/γ Agonism and...
2025-09-25
Explore the advanced roles of WY-14643 (Pirinixic Acid), a selective PPARα agonist, in bridging lipid metabolism regulation and immunometabolic signaling. This article uncovers novel insights into dual PPARα/γ agonism, tumor microenvironment remodeling, and translational applications for metabolic disorder research.
-
Vardenafil HCl Trihydrate: Unveiling Proteoform-Specific ...
2025-09-24
Explore how Vardenafil HCl Trihydrate, a potent PDE5 inhibitor, enables proteoform-specific research in native cell signaling environments. This article uniquely examines its application in advanced membrane protein studies, surpassing standard cGMP pathway analyses.
-
Pseudo-modified Uridine Triphosphate: Mechanistic Insight...
2025-09-23
Explore the mechanistic roles of pseudo-modified uridine triphosphate (Pseudo-UTP) in mRNA synthesis, focusing on RNA stability enhancement, immunogenicity reduction, and translational efficiency. This article provides a detailed, research-driven perspective on Pseudo-UTP for in vitro transcription in mRNA vaccine development and gene therapy.
-
br Conflict of interest br Introduction Colorectal cancer CR
2025-03-03

Conflict of interest Introduction Colorectal cancer (CRC) is one of the major cause of tumor-related morbidity and mortality worldwide. Poor prognosis and consequences of its metastatic spread make CRC the second most common cause of cancer-related deaths in western countries [1]. Apart from o
-
There are some limitations and further
2025-03-03

There are some limitations and further experiments that are required. First, to our surprise, measurement of the cardiomyocyte cross-sectional area in Akt1−/−/iAkt2 KO mice showed comparable areas to WT mouse despite of reduced heart weight. In addition to measuring cardiomyocyte cross-sectional are
-
br AHR expression in cancer Perhaps the earliest
2025-03-03

AHR expression in cancer Perhaps the earliest indicator that the AHR might play an ongoing role in tumorigenesis, independent of its role in generating mutations, was the demonstration that non-genotoxic 2,3,7,8-tetrachlorodibenzo(p)dioxin (TCDD) is a carcinogen in animals and humans [7]. Althoug
16624 records 8/1109 page Previous Next First page 上5页 678910 下5页 Last page